Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for process/pmg6 returned no results
Showing 2506 to 2520 of 2854 results for process

  1. Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]

    In development Reference number: GID-TA10886 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]

    Discontinued Reference number: GID-TA10033

    Technology appraisal guidance
    Discontinued

  3. Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]

    Discontinued Reference number: GID-TA10531

    Technology appraisal guidance
    Discontinued

  4. Rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions [ID463]

    Discontinued Reference number: GID-TAG427

    Technology appraisal guidance
    Discontinued

  5. Lung cancer (non-small cell) - afatinib [ID357]

    Discontinued Reference number: GID-TAG422

    Technology appraisal guidance
    Discontinued

  6. Hypercholesterolemia - mipomersen [ID524]

    Discontinued Reference number: GID-TAG437

    Technology appraisal guidance
    Discontinued

  7. Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]

    In development Reference number: GID-TA11585 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    Discontinued Reference number: GID-TA11086

    Technology appraisal guidance
    Discontinued

  9. Zio XT for detecting cardiac arrhythmias

    In development Reference number: GID-MT591 Expected publication date: TBC

    Medical technologies guidance
    In development

  10. Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]

    Discontinued Reference number: GID-TA10633

    Technology appraisal guidance
    Discontinued

  11. Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]

    Discontinued Reference number: GID-TA10244

    Technology appraisal guidance
    Discontinued

  12. Aptiva for painful diabetic neuropathy (MIB119)

    NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .

    Medtech innovation briefing
    Published
    13 September 2017

  13. Next-generation sequencing panel for solid tumour cancers in children (MIB133)

    NICE has developed a medtech innovation briefing (MIB) on the next-generation sequencing panel for solid tumour cancers in children .

    Medtech innovation briefing
    Published
    8 January 2018

  14. Natural Cycles for monitoring fertility (MIB244)

    NICE has developed a medtech innovation briefing (MIB) on Natural Cycles for monitoring fertility .

    Medtech innovation briefing
    Published
    19 January 2021

  15. Butterfly iQ+ for diagnostic ultrasound imaging (MIB254)

    NICE has developed a medtech innovation briefing (MIB) on Butterfly iQ+ for diagnostic ultrasound imaging .

    Medtech innovation briefing
    Published
    4 March 2021